<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01318460</url>
  </required_header>
  <id_info>
    <org_study_id>AHEPA_CTS-03</org_study_id>
    <nct_id>NCT01318460</nct_id>
  </id_info>
  <brief_title>Prophylactic Administration of Levosimendan in Patients Undergoing Coronary Surgery</brief_title>
  <official_title>Prophylactic Administration of Levosimendan in Patients With Impaired Left Ventricular Function Undergoing Coronary Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AHEPA University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Orion Corporation, Orion Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AHEPA University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present pilot study aims to investigate the effectiveness of the preoperative infusion of
      levosimendan in patients with impaired left ventricular function undergoing coronary artery
      bypass grafting.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Myocardial revascularization in patients with impaired left ventricular function remains a
      serious problem in cardiac surgery. Despite the recent developments with the use of new
      surgical techniques (mini-extracorporeal circulation, off pump surgery) the perioperative
      morbidity and mortality are relatively high. Therapeutic solutions with the use of inotropic
      drugs, as adrenergic agonists and phosphodiesterase inhibitors, have offered important
      improvement to the hemodynamic status of these patients, but they have not considerably
      decreased mortality. These drugs owe their positive inotropic action to the increase of
      intracellular calcium and thereafter they improve the myocardial function.

      Levosimendan (SIMDAX) is a new calcium sensitizer which increases the myocardial
      contractility without particular promotion of the intracellular calcium accumulation.
      Contemporary experimental and clinical data demonstrated the effectiveness of this drug in
      the reduction of surgical mortality to the patients with low left ventricular ejection
      fraction (LVEF) who undergo coronary artery bypass grafting (CABG).

      This is an original prospective randomized controlled study focused on the preoperative use
      of this drug in patients with impaired left ventricular function which is associated with a
      high operative risk (i.e. EuroSCORE). Perioperative myocardial stunning is particularly
      evident in this cohort of patients. Prophylactic administration of levosimendan the day
      before the operation could be translated in improved myocardial performance intraoperatively
      and during the early postoperative period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Left ventricular function</measure>
    <time_frame>Seventh postoperative day</time_frame>
    <description>Left ventricular function as assessed by transthoracic or transesophageal echocardiography on the seventh postoperative day</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Perioperative mortality</measure>
    <time_frame>30 days postoperatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for intraaortic balloon pump</measure>
    <time_frame>1st-7th postoperative day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inotropic support</measure>
    <time_frame>1st-7th postoperative day</time_frame>
    <description>Need for high inotropic support</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total ICU stay</measure>
    <time_frame>1st-7th postoperative day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total length of hospital stay</measure>
    <time_frame>1st-7th postoperative day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time on mechanical ventilation</measure>
    <time_frame>1st-7th postoperative day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiovascular events</measure>
    <time_frame>1st-7th postoperative day</time_frame>
    <description>Perioperative myocardial infarction, stroke, need for revascularization)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morbidity</measure>
    <time_frame>1st-7th postoperative day</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Levosimendan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients treated with prophylactic administration of levosimendan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients managed with placebo administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levosimendan infusion</intervention_name>
    <description>Prophylactic 24h infusion of levosimendan at a dose of 0.1 mg/kg/min</description>
    <arm_group_label>Levosimendan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo infusion</intervention_name>
    <description>Twenty-four hour administration of placebo</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  coronary artery disease which warrants myocardial revascularization with coronary
             artery bypass grafting according to current guidelines

          -  age &lt; 79 years old

          -  left ventricular ejection fraction &lt;= 40%

          -  informed patient's consent

        Exclusion Criteria:

          -  age &lt; 18 years old

          -  emergency surgery

          -  medical history of acute myocardial infarction with ST elevation (STEMI) less than 14
             days old

          -  any severe comorbidity which increases the perioperative risk (i.e. neoplasia,
             rheumatoid arthritis, chronic obstructive pulmonary disease)

          -  need for valvular replacement surgery

          -  redo surgery

          -  serum creatinine &gt; 2 mg/dl

          -  history of malignant cardiac arrhythmias
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyriakos Anastasiadis, MD, FETCS</last_name>
    <role>Principal Investigator</role>
    <affiliation>AHEPA University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christos Papakonstantinou, MD</last_name>
    <role>Study Chair</role>
    <affiliation>AHEPA University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Cardiothoracic Surgery, AHEPA University Hospital</name>
      <address>
        <city>Thessaloniki</city>
        <zip>546 36</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <reference>
    <citation>De Hert SG, Lorsomradee S, Cromheecke S, Van der Linden PJ. The effects of levosimendan in cardiac surgery patients with poor left ventricular function. Anesth Analg. 2007 Apr;104(4):766-73. Erratum in: Anesth Analg. 2007 Jun;104(6):1544. Dosage error in article text.</citation>
    <PMID>17377079</PMID>
  </reference>
  <reference>
    <citation>Tasouli A, Papadopoulos K, Antoniou T, Kriaras I, Stavridis G, Degiannis D, Geroulanos S. Efficacy and safety of perioperative infusion of levosimendan in patients with compromised cardiac function undergoing open-heart surgery: importance of early use. Eur J Cardiothorac Surg. 2007 Oct;32(4):629-33. Epub 2007 Aug 15. Erratum in: Eur J Cardiothorac Surg. 2008 Mar;33(3):521.</citation>
    <PMID>17702589</PMID>
  </reference>
  <reference>
    <citation>Kolseth SM, Nordhaug DO, Stenseth R, Sellevold O, Kirkeby-Garstad I, Wahba A. Prophylactic treatment with levosimendan: a retrospective matched-control study of patients with reduced left ventricular function. Eur J Cardiothorac Surg. 2009 Dec;36(6):1024-30. doi: 10.1016/j.ejcts.2009.05.001. Epub 2009 Jul 9.</citation>
    <PMID>19592266</PMID>
  </reference>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 17, 2011</study_first_submitted>
  <study_first_submitted_qc>March 17, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2011</study_first_posted>
  <last_update_submitted>March 11, 2014</last_update_submitted>
  <last_update_submitted_qc>March 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 12, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>AHEPA University Hospital</investigator_affiliation>
    <investigator_full_name>Kyriakos Anastasiadis</investigator_full_name>
    <investigator_title>Head of Cardiothoracic Department</investigator_title>
  </responsible_party>
  <keyword>coronary artery disease</keyword>
  <keyword>levosimendan</keyword>
  <keyword>coronary artery bypass grafting</keyword>
  <keyword>cardiac surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simendan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

